In the current study, we utilized different patient-derived melanoma cell lines (BAKP, BAKR, and POT) with CRISPR/Cas9-mediated CD133 KO, as well as Dox-inducible CD133 expression in two different cell lines (BAKP and POT) and showed that CD133 is part of a CD133/AKT/BAD-dependent pathway, working in combination with a previously characterized RAS/RAF/MEK/ERK pathway [63]. Here, PROM1 is linked to melanoma.